Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review

Gastric cancer is one of the most common oncological diseases at the present time, so research in this area is very significant and relevant. Immunological checkpoint inhibitors have previously demonstrated their effectiveness and safety in various solid tumors, however, with regard to stomach canc...

Full description

Bibliographic Details
Published in:	Успехи молекулярной онкологии
Main Authors:	T. N. Sotnikova, N. V. Danilova, P. G. Malkov, T. V. Polushkina
Format:	Article
Language:	Russian
Published:	ABV-press 2023-07-01
Subjects:	gastric cancer immune cells ligand of programmed cell death tumor programmed death ligand 1 receptors signaling pathways
Online Access:	https://umo.abvpress.ru/jour/article/view/542

Similar Items

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
by: Yuan Gao, et al.
Published: (2017-07-01)

Programmed death receptor-1/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer
by: Jin Shi, et al.
Published: (2024-10-01)

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
by: Qiang Liu, et al.
Published: (2017-01-01)

Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer
by: Jee Hyun Ahn, et al.
Published: (2017-12-01)

PD-L1 and PD-1 in immune regulation and their implications in blood cancers
by: Parisa Shiri Aghbash, et al.
Published: (2024-10-01)

A comparative study to assess the increased expression of programmed cell death-1 (PD1) and programmed cell death- ligand-1 (PDL1) in oral potentially malignant disorders and oral squamous cell carcinoma
by: Sonalika Srivastava, et al.
Published: (2023-01-01)

Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
by: ZENG Fei, et al.
Published: (2021-10-01)

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
by: Rachel M. Gibbons Johnson, et al.
Published: (2017-08-01)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
by: Min Liu, et al.
Published: (2020-08-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
by: Eman Eissa, et al.
Published: (2022-01-01)

Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2019-01-01)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
by: Joon Seon Song, et al.
Published: (2019-10-01)

Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease
by: Hiroyuki Goto, et al.
Published: (2021-01-01)

Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report
by: Masanori Harada, et al.
Published: (2021-01-01)

Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer
by: Setyo Teguh Waluyo, et al.
Published: (2024-03-01)

Comparison of Immune Checkpoint Molecules <i>PD-1</i> and <i>PD-L1</i> in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence
by: Wei Yu, et al.
Published: (2022-02-01)

Role of Computed Tomography in Predicting Programmed Death Ligand-1 Positivity in Gastric Adenocarcinoma
by: Yu ZH, et al.
Published: (2025-02-01)

Expression and clinical significance of PD-1, PD-L1 and tumor infiltrating lymphocytes in neuroblastoma
by: QIAO Jiahua*, HAO Ziqi, HUANG Ye, WEI Junni, LI Suhong
Published: (2024-02-01)

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study
by: Shreya Ghosh, et al.
Published: (2023-11-01)

Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review
by: Gilbert Lazarus, et al.
Published: (2019-10-01)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
by: Fereshteh Ameli, et al.
Published: (2022-08-01)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
by: Lei Wang, et al.
Published: (2018-06-01)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
by: Yiming Wang, et al.
Published: (2018-03-01)

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
by: Seher Şener, et al.
Published: (2021-10-01)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
by: Yu-Tzu Tai, et al.
Published: (2018-08-01)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
by: Jossie Rotman, et al.
Published: (2020-12-01)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
by: Ji Hye Kim, et al.
Published: (2020-03-01)

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
by: Xiang Chen, et al.
Published: (2024-02-01)

A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters
by: Sudha Sudha, et al.
Published: (2024-03-01)

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events
by: Tongji XIE, et al.
Published: (2020-07-01)

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01)

Risk of interstitial lung disease with the use of programmed cell death 1 (PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis
by: Lijuan Guo, et al.
Published: (2024-04-01)

Programmed cell death-ligand 1 expression in correlation with human papillomavirus status in cervical cancer: A 1-year retrospective study
by: Kaumudi Konkay, et al.
Published: (2025-01-01)

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma
by: Juan Chipollini, et al.
Published: (2018-10-01)

Obesity and lung cancer – is programmed death ligand-1 (PD-1L) expression a connection?
by: Jakub Krzysztof Gałązka, et al.
Published: (2024-01-01)

Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review
by: Peifeng Chen, et al.
Published: (2025-03-01)

Relationship between serum PD-L1 levels and prognosis of gastric cancer patients
by: CHEN Changqiang, YAN Xiaowei, HU Jiele, BAO Xiting, XIANG Ming, JIANG Songyao
Published: (2024-05-01)